halofenate has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clarke, HJ; Clemens, LE; Favelyukis, S; Gregoire, FM; Gustafson, TA; Lavan, BE; Lenhard, J; Mu, Y; Rentzeperis, D; Sears, DD; Zhang, F | 1 |
| Allen, T; Bell, A; Clemens, LE; Gregoire, F; Gustafson, TA; Moodie, SA; Muscat, GE; Smith, A; Zhang, F | 1 |
2 other study(ies) available for halofenate and Insulin Resistance
| Article | Year |
|---|---|
MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drug Partial Agonism; Edema; Halofenate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Models, Biological; PPAR gamma; Rats; Rats, Zucker; Stereoisomerism; Substrate Specificity; Thiazolidinediones; Transcriptional Activation; Weight Gain | 2009 |
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus; Gene Expression Regulation; Halofenate; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Mice; Mice, Obese; PPAR gamma; Protein Structure, Tertiary; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Two-Hybrid System Techniques | 2006 |